These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 10706870)

  • 1. Cyclophosphamide induces type I interferon and augments the number of CD44(hi) T lymphocytes in mice: implications for strategies of chemoimmunotherapy of cancer.
    Schiavoni G; Mattei F; Di Pucchio T; Santini SM; Bracci L; Belardelli F; Proietti E
    Blood; 2000 Mar; 95(6):2024-30. PubMed ID: 10706870
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice.
    Proietti E; Greco G; Garrone B; Baccarini S; Mauri C; Venditti M; Carlei D; Belardelli F
    J Clin Invest; 1998 Jan; 101(2):429-41. PubMed ID: 9435316
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adoptive immunotherapy with transient anti-CD4 treatment enhances anti-tumor response by increasing IL-18Rα
    Kim SH; Cho E; Kim YI; Han C; Choi BK; Kwon BS
    Nat Commun; 2021 Sep; 12(1):5314. PubMed ID: 34493727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Defining the ability of cyclophosphamide preconditioning to enhance the antigen-specific CD8+ T-cell response to peptide vaccination: creation of a beneficial host microenvironment involving type I IFNs and myeloid cells.
    Salem ML; Kadima AN; El-Naggar SA; Rubinstein MP; Chen Y; Gillanders WE; Cole DJ
    J Immunother; 2007 Jan; 30(1):40-53. PubMed ID: 17198082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unraveling cancer chemoimmunotherapy mechanisms by gene and protein expression profiling of responses to cyclophosphamide.
    Moschella F; Valentini M; Aricò E; Macchia I; Sestili P; D'Urso MT; Alessandri C; Belardelli F; Proietti E
    Cancer Res; 2011 May; 71(10):3528-39. PubMed ID: 21444678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aging leads to disturbed homeostasis of memory phenotype CD8(+) cells.
    Zhang X; Fujii H; Kishimoto H; LeRoy E; Surh CD; Sprent J
    J Exp Med; 2002 Feb; 195(3):283-93. PubMed ID: 11828003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose cyclophosphamide-mediated anti-tumor effects by the superior expansion of CD44(high) cells after their selective depletion.
    Hong SH; Yoon IH; Kim YH; Yang SH; Park MJ; Nam HY; Kim B; Kim Y; Park CS; Park CG
    Immunobiology; 2010 Mar; 215(3):182-93. PubMed ID: 19464751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclophosphamide eradicates murine immunogenic tumor coding for a non-self-antigen and induces antitumor immunity.
    Salem ML; El-Naggar SA; Mahmoud HA; Elgharabawy RM; Bader AM
    Int J Immunopathol Pharmacol; 2018; 32():2058738418796591. PubMed ID: 30270681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adoptive transfer of ex vivo-activated memory T-cell subsets with cyclophosphamide provides effective tumor-specific chemoimmunotherapy of advanced metastatic murine melanoma and carcinoma.
    Gold JE; Zachary DT; Osband ME
    Int J Cancer; 1995 May; 61(4):580-6. PubMed ID: 7759164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of interferon regulatory factor 1 in governing Treg depletion, Th1 polarization, inflammasome activation and antitumor efficacy of cyclophosphamide.
    Buccione C; Fragale A; Polverino F; Ziccheddu G; Aricò E; Belardelli F; Proietti E; Battistini A; Moschella F
    Int J Cancer; 2018 Mar; 142(5):976-987. PubMed ID: 28975621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Type I interferon is the primary regulator of inducible Ly-6C expression on T cells.
    Schlueter AJ; Krieg AM; de Vries P; Li X
    J Interferon Cytokine Res; 2001 Aug; 21(8):621-9. PubMed ID: 11559440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative.
    Ghiringhelli F; Larmonier N; Schmitt E; Parcellier A; Cathelin D; Garrido C; Chauffert B; Solary E; Bonnotte B; Martin F
    Eur J Immunol; 2004 Feb; 34(2):336-44. PubMed ID: 14768038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nitric oxide-producing CD11b(+)Ly-6G(Gr-1)(+)CD31(ER-MP12)(+) cells in the spleen of cyclophosphamide-treated mice: implications for T-cell responses in immunosuppressed mice.
    Angulo I; de las Heras FG; García-Bustos JF; Gargallo D; Muñoz-Fernández MA; Fresno M
    Blood; 2000 Jan; 95(1):212-20. PubMed ID: 10607705
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunosuppressive myeloid cells induced by chemotherapy attenuate antitumor CD4+ T-cell responses through the PD-1-PD-L1 axis.
    Ding ZC; Lu X; Yu M; Lemos H; Huang L; Chandler P; Liu K; Walters M; Krasinski A; Mack M; Blazar BR; Mellor AL; Munn DH; Zhou G
    Cancer Res; 2014 Jul; 74(13):3441-53. PubMed ID: 24780756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced dendritic cell-based immunotherapy using low-dose cyclophosphamide and CD25-targeted antibody for transplanted Lewis lung carcinoma cells.
    Son CH; Bae JH; Lee HR; Shin DY; Yang K; Park YS
    J Immunother; 2015 Apr; 38(3):107-15. PubMed ID: 25751500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Growth-inhibition of S180 residual-tumor by combination of cyclophosphamide and chitosan oligosaccharides in vivo.
    Zhai X; Yuan S; Yang X; Zou P; Shao Y; Abd El-Aty AM; Hacımüftüoğlu A; Wang J
    Life Sci; 2018 Jun; 202():21-27. PubMed ID: 29626528
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Macrophages Induce Long-Term Trapping of γδ T Cells with Innate-like Properties within Secondary Lymphoid Organs in the Steady State.
    Audemard-Verger A; Rivière M; Durand A; Peranzoni E; Guichard V; Hamon P; Bonilla N; Guilbert T; Boissonnas A; Auffray C; Eberl G; Lucas B; Martin B
    J Immunol; 2017 Sep; 199(6):1998-2007. PubMed ID: 28779024
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phenotypic changes induced by interferon in resting T cells: major enhancement of Ly-6 antigen expression.
    Dumont FJ; Palfree RG; Coker LZ
    J Immunol; 1986 Jul; 137(1):201-10. PubMed ID: 2423601
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful immunotherapy of the highly metastatic murine ESb lymphoma with sensitized CD8+ T cells and IFN-alpha/beta.
    Kaido T; Maury C; Schirrmacher V; Gresser I
    Int J Cancer; 1994 May; 57(4):538-43. PubMed ID: 8181857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Importance of signaling via the IFN-alpha/beta receptor on host cells for the realization of the therapeutic benefits of cyclophosphamide for mice bearing a large MOPC-315 tumor.
    Mokyr MB; Place AT; Artwohl JE; Valli VE
    Cancer Immunol Immunother; 2006 Apr; 55(4):459-68. PubMed ID: 15965646
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.